Hq Spclt Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HQ SPCLT PHARMA, and when can generic versions of HQ SPCLT PHARMA drugs launch?
HQ SPCLT PHARMA has fourteen approved drugs.
There are six US patents protecting HQ SPCLT PHARMA drugs.
There are twelve patent family members on HQ SPCLT PHARMA drugs in nine countries and ninety-one supplementary protection certificates in fifteen countries.
Summary for Hq Spclt Pharma
| International Patents: | 12 |
| US Patents: | 6 |
| Tradenames: | 16 |
| Ingredients: | 11 |
| NDAs: | 14 |
Drugs and US Patents for Hq Spclt Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hq Spclt Pharma | MEROPENEM | meropenem | INJECTABLE;INJECTION | 210773-001 | Aug 16, 2019 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Hq Spclt Pharma | DEXMEDETOMIDINE HYDROCHLORIDE | dexmedetomidine hydrochloride | SOLUTION;INTRAVENOUS | 206628-004 | Jun 22, 2018 | RX | Yes | No | 9,717,796 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Hq Spclt Pharma | MEROPENEM | meropenem | POWDER;INTRAVENOUS | 215212-001 | Jul 26, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Hq Spclt Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Hq Spclt Pharma | PLATINOL-AQ | cisplatin | INJECTABLE;INJECTION | 018057-003 | Jul 18, 1984 | 4,310,515 | ⤷ Try a Trial |
| Hq Spclt Pharma | PLATINOL | cisplatin | INJECTABLE;INJECTION | 018057-001 | Approved Prior to Jan 1, 1982 | 5,562,925 | ⤷ Try a Trial |
| Hq Spclt Pharma | CISPLATIN | cisplatin | INJECTABLE;INJECTION | 018057-004 | Nov 8, 1988 | 5,562,925 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Hq Spclt Pharma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 201807466 | ⤷ Try a Trial |
| South Korea | 20150132835 | ⤷ Try a Trial |
| European Patent Office | 3429574 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Hq Spclt Pharma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1853250 | C300673 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220 |
| 0933372 | 13/2008 | Austria | ⤷ Try a Trial | PRODUCT NAME: FOSAMPRENAVIR ALS FOSAMPRENAVIR-CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001 - EU/1/04/282/002 (MITTEILUNG VOM 14.07.2004) 20040713 |
| 2365988 | CA 2018 00006 | Denmark | ⤷ Try a Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM AND ANY SALTS AND DERIVATIVES THEREOF; REG. NO/DATE: EU/1/17/1179/001-009 20170721 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
